---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107988"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:40:07.216126+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet ADI-001 shows robust tissue trafficking, complete B cell depletion in Phase 1

## Summary
- Mean exposure of 236,701 CAR T cells per million in lymph node biopsies across all dose levels.
- At 1E9 dose, 27-64% of total cellular material in evaluable biopsies, exceeding published autologous alpha-beta CAR T levels.
- Complete CD19+ B cell depletion observed in secondary lymphoid tissue concurrent with trafficking and activation.
- Data highlight potential best-in-class profile vs. anti-CD20 antibodies that failed to deplete B cells in tissues.
- Initial clinical data from autoimmune programs (lupus nephritis, SLE, systemic sclerosis, AAV) expected H1 2025.

## SEC filing metadata
- accession: 0000950170-24-107988
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024107988/0000950170-24-107988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024107988/acet-20240919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107988
- JSON: https://secwatch.observer/filing/0000950170-24-107988.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.